Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer

被引：9

作者：

Nagashio, Kenji ^{[1
]}

Tajiri, Kazuko ^{[1
]}

Sato, Kimi ^{[1
]}

Ieda, Masaki ^{[1
]}

机构：

[1] Univ Tsukuba, Fac Med, Dept Cardiol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan

来源：

INTERNATIONAL HEART JOURNAL | 2021年 / 62卷 / 05期

关键词：

Cardio-oncology; Onco-cardiology; CTRCD; Heart failure; EGFR-TKI; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER;

D O I：

10.1536/ihj.21-130

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is a targeted drug used for the treatment of non-small cell lung cancer (NSCLC). Erlotinib is considered relatively safe and generally well-tolerated, with rarely reported cardiac side effects. Herein, we report a case of cardiomyopathy that developed during erlotinib treatment for NSCLC. Two months after erlotinib initiation, our 70 year-old female patient complained of progressive dyspnea, and a diagnostic endomyocardial biopsy confirmed non-specific cardiomyopathy, indicating erlotinib-induced cardiomyopathy. We believed that continued administration of erlotinib would exacerbate her heart failure, while treatment of the heart failure with intensive monitoring would allow the administration of erlotinib to be continued. This case report highlights the potential cardiotoxic effects of erlotinib and suggests the need for close clinical and echocardiographic follow-up of patients receiving erlotinib.

引用

页码：1171 / 1175

页数：5

共 10 条

[1] Acute myocardial infarction following erlotinib treatment for NSCLC: A case report [J].

Ding, Shanshan ;

Long, Fei ;

Jiang, Shujuan .

ONCOLOGY LETTERS, 2016, 11 (06) :4240-4244

[2] Alternative signaling:: cardiomyocyte β1-adrenergic receptors signal through EGFRs [J].

Engelhardt, Stefan .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (09) :2396-2398

[3] Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? [J].

Kus, Tulay ;

Aktas, Gokmen ;

Sevinc, Alper ;

Kalender, Mehmet Emin ;

Camci, Celaletdin .

ONCOTARGETS AND THERAPY, 2015, 8 :1341-1343

[4] Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity A Phase I Trial [J].

Leong, Darryl P. ;

Cosman, Tammy ;

Alhussein, Muhammad M. ;

Tyagi, Nidhi Kumar ;

Karampatos, Sarah ;

Barron, Carly C. ;

Wright, Douglas ;

Tandon, Vikas ;

Magloire, Patrick ;

Joseph, Philip ;

Conen, David ;

Devereaux, P. J. ;

Ellis, Peter M. ;

Mukherjee, Som D. ;

Dhesy-Thind, Sukhbinder .

JACC: CARDIOONCOLOGY, 2019, 1 (01) :1-10

[5] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[6] b-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection [J].

Noma, Takahisa ;

Lemaire, Anthony ;

Prasad, Sathyamangla V. Naga ;

Barki-Harrington, Liza ;

Tilley, Douglas G. ;

Chen, Juhsien ;

Le Corvoisier, Philippe ;

Violin, Jonathan D. ;

Wei, Huijun ;

Lefkowitz, Robert J. ;

Rockman, Howard A. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (09) :2445-2458

[7] Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report [J].

Pinquie, Francois ;

de Chabot, Gonzagues ;

Urban, Thierry ;

Hureaux, Jose .

ONCOLOGY, 2016, 90 (03) :176-177

[8] Erlotinib in Advanced Non-small Cell Lung Cancer Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study [J].

Reck, Martin ;

van Zandwijk, Nico ;

Gridelli, Cesare ;

Baliko, Zoltan ;

Rischin, Danny ;

Allan, Simon ;

Krzakowski, Maciej ;

Heigener, David .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) :1616-1622

[9] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[10] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

← 1 →